Table 2 Association between patient characteristics at the time of radiotherapy and response to treatment

Age (per year)

0.99 (0.98–1.01)

0.39

0.99 (0.97–1.01)

0.50

Sex

 Male

1 (Reference)

1 (Reference)

 Female

1.50 (1.01–2.24)

0.045

1.35 (0.86–2.13)

0.19

ECOG performance status (per point)

0.68 (0.53–0.86)

0.002

0.71 (0.55–0.93)

0.01

Smoking history

 Nonsmoker

1 (Reference)

1 (Reference)

 Active smoker

1.02 (0.55–1.88)

0.96

1.79 (0.89–3.60)

0.10

 Former smoker

1.13 (0.62–2.04)

0.69

1.72 (0.88–3.35)

0.11

Pathology

 NSCLC without targetable mutation

1 (Reference)

1 (Reference)

 NSCLC with targetable EGFR mutation

2.02 (1.21–3.38)

0.008

2.46 (1.35–4.51)

0.003

 NSCLC with ALK mutation

0.32 (0.02–5.17)

0.42

0.53 (0.06–4.57)

0.56

 Small cell carcinoma

0.70 (0.25–1.95)

0.50

0.93 (0.31–2.83)

0.90

 Mesothelioma

1.08 (0.43–2.75)

0.87

1.49 (0.50–4.41)

0.47

 Not histologically confirmed

3.36 (0.71–15.85)

0.13

3.11 (0.60–16.22)

0.18

Prior chemotherapy lines, excluding TKIs

 None

1 (Reference)

1 (Reference)

 At least 1

0.87 (0.53–1.43)

0.57

0.76 (0.45–1.29)

0.31

Radiotherapy fractions

 Single

1 (Reference)

1 (Reference)

 Multiple

0.76 (0.45–1.28)

0.30

1.03 (0.60–1.78)

0.92